25th Annual St. Jude/PIDS Conference

Wednesday, March 4, 2026, 7:00 AM - Friday, March 6, 2026, 7:00 PM, MTC Auditorium

The St. Jude-PIDS Pediatric Infectious Diseases Research Conference celebrates its 25th year of education, collaboration, and innovation. The milestone meeting will convene March 4-6, 2026 in Memphis, TN and virtually.

To kick off this special anniversary year, there will be a Pre-Conference Career Development Event for Trainees on Tuesday, March 3, 2026 at the Peabody Memphis. This event includes a career panel, guided conversation on special topics, networking opportunities, personalized discussions and direct engagement with faculty (in-person only).

In-person or virtual registration is now open. In-person registration will close at 3:00 p.m. CT, Monday, February 16, 2026. Virtual registration will remain available throughout the conference.

St. Jude Children's Research Hospital is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

St. Jude Children’s Research Hospital designates this Live Activity for a maximum of 17.00 AMA PRA Category 1 Credits^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

AMA PRA Category 1 Credits™ (17.00 hours)

The official hotel for the 25th Annual St. Jude/PIDS Pediatric Infectious Diseases Research Conference will be The Peabody Hotel. A room block has been established. The window to book at the special room rate is Sunday, February 8, 2026.

The faculty for this activity are listed below. Click to view the faculty member's financial disclosure information and bio. 

Mitigation of Relevant Financial Relationships

St Jude Children's Research Hospital adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (ie, companies whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.